摘要
Targeted therapy has been widely demonstrated as an effective strategy to treat cancers,the leading cause of death in the world.This minireview summarizes the technical platforms and methodologies utilized to develop and engineer therapeutic monoclonal antibodies and antibody-drug conjugates.First,the USA FDA approved monoclonal antibody(mAb)-based targeted therapies are reviewed.Then the representative innovative chimeric,humanized and fully human anti-cancer antibodies and antibody-drug conjugates are described.Finally,the past and predictive market trend of therapeutic antibodies is discussed.
基金
supported by National Institutes of Health R21CA226491-01A1 (X.M.L.),1R01CA238273-01A1 (X.M.L.) and 1R01CA242917-01A1(X.M.L.)
